%0 Journal Article
%T Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data
%A Evelien Roekevisch
%A Jan Dositheus Bos
%A Louise Anna Andrea Gerbens
%A Mandy Elvira Schram
%A Marijke Willemijn Doroth¨¦e Brouwer
%A Mariska Maria Geertruida Leeflang
%A Phyllis Ira Spuls
%J Journal of Allergy and Clinical Immunology
%D 2018
%R 10.1016/j.jaci.2017.09.033
%X Long-term data of methotrexate (MTX) and azathioprine (AZA) in atopic dermatitis (AD)
are lacking. Previously, we published the results of a randomized controlled trial
of 42 adults with severe AD treated with MTX or AZA for 12 to 24£¿weeks. Both MTX and
AZA induced significant reductions in SCORing Atopic Dermatitis (SCORAD) index at
12 and 24£¿weeks after baseline, without a significant difference between treatments.1
To assess long-term efficacy and safety of MTX versus AZA, all 42 patients were asked
to participate in an observational follow-up study to be evaluated 3 monthly for 2£¿years.
%U https://www.jacionline.org/article/S0091-6749(17)31657-3/abstract